Cargando…

Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study

OBJECTIVES: To determine the association of long-term use of antipsychotics with the risk of dyslipidaemia. DESIGN: A hospital-based cohort study. SETTING: Electronic health record data of adult mental health inpatients in all 19 specialised psychiatric hospitals in Beijing from 1 January 2005 to 31...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Qiuyue, Yang, Fude, Ma, Botao, Jing, Wenzhan, Liu, Jue, Guo, Moning, Li, Juan, Wang, Zhiren, Liu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853033/
https://www.ncbi.nlm.nih.gov/pubmed/33518524
http://dx.doi.org/10.1136/bmjopen-2020-043259
_version_ 1783645900563808256
author Ma, Qiuyue
Yang, Fude
Ma, Botao
Jing, Wenzhan
Liu, Jue
Guo, Moning
Li, Juan
Wang, Zhiren
Liu, Min
author_facet Ma, Qiuyue
Yang, Fude
Ma, Botao
Jing, Wenzhan
Liu, Jue
Guo, Moning
Li, Juan
Wang, Zhiren
Liu, Min
author_sort Ma, Qiuyue
collection PubMed
description OBJECTIVES: To determine the association of long-term use of antipsychotics with the risk of dyslipidaemia. DESIGN: A hospital-based cohort study. SETTING: Electronic health record data of adult mental health inpatients in all 19 specialised psychiatric hospitals in Beijing from 1 January 2005 to 31 December 2018 was obtained. PARTICIPANTS: Participants were inpatients aged 18 years or older with at least two admissions, excluding those with diagnosed dyslipidaemia and fatty liver at the first admission. We included 22 329 adult inpatients with no dyslipidaemia and fatty liver at baseline. The exposure was antipsychotics use, defined as antipsychotics prescription in the treatment procedures of medical record preceding dyslipidaemia diagnosis during the follow-up period. 15 930 (71.34%) had antipsychotics use, and 6399 (28.66%) never had antipsychotics use. We used the length of follow-up as proxy for the duration of antipsychotics exposure. PRIMARY OUTCOME MEASURES: The primary outcome was newly recorded dyslipidaemia defined by International Classification of Diseases, 10th Revision codes. RESULTS: 4069 inpatients had newly recorded dyslipidaemia during 73 418.07 person-years, the incidence rate was 5.54 per 100 person-years. The incidence rate was 7.22 per 100 person-years in the exposed group and 3.43 per 100 person-years in the unexposed group. Results of multivariate analysis showed that antipsychotics use was associated with higher risk of dyslipidaemia (adjusted HR, aHR 2.41, 95% CI 2.24 to 2.59, p<0.001), regardless of the duration of antipsychotics use. Inpatients aged 18–29 years had higher risk of dyslipidaemia (aHR 3.38, 95% CI 2.77 to 4.12, p=0.004) than those in other age groups. Inpatients without hypertension had substantially higher risk of dyslipidaemia after antipsychotic exposure. CONCLUSIONS: Both short-term and long-term antipsychotics use was associated with higher risk of dyslipidaemia among Chinese inpatients with mental illness. Dyslipidaemia was especially prominent in young patients and those without hypertension.
format Online
Article
Text
id pubmed-7853033
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78530332021-02-11 Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study Ma, Qiuyue Yang, Fude Ma, Botao Jing, Wenzhan Liu, Jue Guo, Moning Li, Juan Wang, Zhiren Liu, Min BMJ Open Mental Health OBJECTIVES: To determine the association of long-term use of antipsychotics with the risk of dyslipidaemia. DESIGN: A hospital-based cohort study. SETTING: Electronic health record data of adult mental health inpatients in all 19 specialised psychiatric hospitals in Beijing from 1 January 2005 to 31 December 2018 was obtained. PARTICIPANTS: Participants were inpatients aged 18 years or older with at least two admissions, excluding those with diagnosed dyslipidaemia and fatty liver at the first admission. We included 22 329 adult inpatients with no dyslipidaemia and fatty liver at baseline. The exposure was antipsychotics use, defined as antipsychotics prescription in the treatment procedures of medical record preceding dyslipidaemia diagnosis during the follow-up period. 15 930 (71.34%) had antipsychotics use, and 6399 (28.66%) never had antipsychotics use. We used the length of follow-up as proxy for the duration of antipsychotics exposure. PRIMARY OUTCOME MEASURES: The primary outcome was newly recorded dyslipidaemia defined by International Classification of Diseases, 10th Revision codes. RESULTS: 4069 inpatients had newly recorded dyslipidaemia during 73 418.07 person-years, the incidence rate was 5.54 per 100 person-years. The incidence rate was 7.22 per 100 person-years in the exposed group and 3.43 per 100 person-years in the unexposed group. Results of multivariate analysis showed that antipsychotics use was associated with higher risk of dyslipidaemia (adjusted HR, aHR 2.41, 95% CI 2.24 to 2.59, p<0.001), regardless of the duration of antipsychotics use. Inpatients aged 18–29 years had higher risk of dyslipidaemia (aHR 3.38, 95% CI 2.77 to 4.12, p=0.004) than those in other age groups. Inpatients without hypertension had substantially higher risk of dyslipidaemia after antipsychotic exposure. CONCLUSIONS: Both short-term and long-term antipsychotics use was associated with higher risk of dyslipidaemia among Chinese inpatients with mental illness. Dyslipidaemia was especially prominent in young patients and those without hypertension. BMJ Publishing Group 2021-01-31 /pmc/articles/PMC7853033/ /pubmed/33518524 http://dx.doi.org/10.1136/bmjopen-2020-043259 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Mental Health
Ma, Qiuyue
Yang, Fude
Ma, Botao
Jing, Wenzhan
Liu, Jue
Guo, Moning
Li, Juan
Wang, Zhiren
Liu, Min
Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study
title Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study
title_full Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study
title_fullStr Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study
title_full_unstemmed Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study
title_short Risk of dyslipidaemia with antipsychotic drug treatment in Chinese inpatients with mental illness: a hospital-based cohort study
title_sort risk of dyslipidaemia with antipsychotic drug treatment in chinese inpatients with mental illness: a hospital-based cohort study
topic Mental Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853033/
https://www.ncbi.nlm.nih.gov/pubmed/33518524
http://dx.doi.org/10.1136/bmjopen-2020-043259
work_keys_str_mv AT maqiuyue riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT yangfude riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT mabotao riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT jingwenzhan riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT liujue riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT guomoning riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT lijuan riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT wangzhiren riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy
AT liumin riskofdyslipidaemiawithantipsychoticdrugtreatmentinchineseinpatientswithmentalillnessahospitalbasedcohortstudy